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Abstract
Background: The effects of neuromuscular electrical stimulation (NMES) in critically ill patients after cardiothoracic
surgery are unknown. The objectives were to investigate whether NMES prevents loss of muscle layer thickness
(MLT) and strength and to observe the time variation of MLT and strength from preoperative day to hospital
discharge.
Methods: In this randomized controlled trial, 54 critically ill patients were randomized into four strata based on
the SAPS II score. Patients were blinded to the intervention. In the intervention group, quadriceps muscles were
electrically stimulated bilaterally from the first postoperative day until ICU discharge for a maximum of 14 days. In
the control group, the electrodes were applied, but no electricity was delivered. The primary outcomes were MLT
measured by ultrasonography and muscle strength evaluated with the Medical Research Council (MRC) scale. The
secondary functional outcomes were average mobility level, FIM score, Timed Up and Go Test and SF-12 health
survey. Additional variables of interest were grip strength and the relation between fluid balance and MLT. Linear
mixed models were used to assess the effect of NMES on MLT, MRC score and grip strength.
Results: NMES had no significant effect on MLT. Patients in the NMES group regained muscle strength 4.5 times
faster than patients in the control group. During the first three postoperative days, there was a positive correlation
between change in MLT and cumulative fluid balance (r = 0.43, P = 0.01). At hospital discharge, all patients regained
preoperative levels of muscle strength, but not of MLT. Patients did not regain their preoperative levels of average
mobility (P = 0.04) and FIM score (P = 0.02) at hospital discharge, independent of group allocation.
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Conclusions: NMES had no effect on MLT, but was associated with a higher rate in regaining muscle strength
during the ICU stay. Regression of intramuscular edema during the ICU stay interfered with measurement of
changes in MLT. At hospital discharge patients had regained preoperative levels of muscle strength, but still
showed residual functional disability and decreased MLT compared to pre-ICU levels in both groups.
Trial registration: Clinicaltrials.gov identifier NCT02391103. Registered on 7 March 2015.
Keywords: Electrical stimulation therapy, ICU-acquired weakness, Muscular atrophy, Ultrasonography, Muscle layer
thickness, Edema, Muscle strength, Critically ill, Cardiothoracic surgery, Functional outcomes
Background
Intensive care unit-acquired weakness (ICUAW) affects
24–77 % of patients with an ICU stay longer than 1
week [1]. The main risk factors for ICUAW develop-
ment include sepsis, catecholamine administration,
hyperglycemia, ICU length of stay and immobility [1].
ICUAW is associated with symptomatic aspirations [2]
and increased hospital mortality [1].
At 5 years after ICU discharge, the 6-minute walking
distance (6MWD) and the quality of life assessed by the
36-Item Short Form (SF-36) questionnaire are still de-
creased [3]. Activities in daily living and cognitive func-
tion are impaired even up to 8 years after ICU discharge
[4]. In order to prevent these tremendous consequences
of ICUAW, early diagnosis and treatment may be de-
cisive. In nonsedated patients, ICUAW is diagnosed
when Medical Research Council (MRC) sum score is
below 48 out of 60 points or when mean MRC score is
below 4 out of 5 points in all testable muscle groups [5].
In sedated patients, muscle ultrasonography may be a
diagnostic tool to detect muscle wasting [6, 7]. It is un-
clear whether muscular ultrasonography is influenced by
edema [6–13]. Among different treatment modalities of
ICUAW [14, 15], neuromuscular electrical stimulation
(NMES) is a feasible therapy for neuromuscular activa-
tion in sedated patients. Yet, the effects of NMES on
muscle mass and strength are still unclear in critically ill
patients: randomized controlled trials either showed no ef-
fect [11, 16, 17] or (partially) beneficial effects [9, 17–22].
Moreover, most prior NMES studies did not assess any
functional outcomes at hospital discharge to assess the po-
tential effect of NMES on the patient's functional status
after the ICU stay [9, 11, 17, 19–21]. NMES can be safely
applied in critically ill patients with external pacemakers
after cardiothoracic surgery [23, 24].
To date, no randomized controlled trial has evaluated
the effects of NMES on muscle mass and strength in a
cardiothoracic surgery patient population. Given that
cardiovascular disease is the leading cause of death
worldwide [25], more attention needs to be addressed to
the rehabilitation of critically ill patients after cardiac
surgery. Neither have trials assessed muscle mass,
strength and functional status altogether prior to critical
illness, which is necessary for evaluating change in
muscle mass and strength in relation to preoperative
values.
Therefore the first objective was to investigate whether
early NMES is effective in preventing loss of MLT and
strength in critically ill patients after cardiothoracic sur-
gery. The second objective was to observe the time vari-
ation of muscle layer thickness (MLT) and muscle
strength from preoperative day to hospital discharge. To
adjust for possible confounders for measurement of MLT,
daily fluid balance was assessed during the ICU stay.
Methods
Study design and population
The prospective, randomized, controlled, single-blind trial
Catastim 2 was carried out at the Division of Cardiothor-
acic and Vascular Anesthesia and Intensive Care Medicine
of the General Hospital affiliated to the Medical University
of Vienna from May 2011 to July 2012 (clinicaltrials.gov
identifier: NCT02391103). Patients were blinded to the
NMES/sham stimulation. Nonblinded assessors performed
the ultrasound scans; however, the evaluators measuring
MLT were blinded to patients’ group assignment. The as-
sessors of muscle strength and the secondary outcomes
were not blinded to patients’ group assignment. Ethical ap-
proval was obtained from the ethics committee of the
Medical University of Vienna in 2010 (number 1072/
2010). Patients were included if they underwent cardio-
thoracic surgery and were anticipated to stay in the ICU
for at least 48 hours. Patients were excluded if they were
younger than 18 years, had a body mass index of more
than 40 kg/m2, had metal implants or skin lesions in the
stimulation area, had neuromuscular diseases, had an im-
planted ventricular assist device or intra-aortic balloon
pump. After submission of a protocol amendment in June
2011, a twofold study setting was defined in order to re-
cruit patients not only before, but also after cardiothoracic
surgery. In cohort A, patients were recruited before sur-
gery. In cohort B, patients were recruited after surgery. Re-
cruitment of patients after surgery primarily allowed
inclusion of patients after urgent nonelective surgeries
such as heart transplantations, who could not be seen pre-
operatively. Written informed consent was obtained from
Fischer et al. Critical Care  (2016) 20:30 Page 2 of 13
patients in cohort A. Patients in cohort B were included in
the trial while sedated to be later informed of their partici-
pation. The inclusion of sedated patients in cohort B with-
out providing written informed consent was approved by
the ethics committee of the Medical University of Vienna.
Randomization
For all patients, randomization was performed on post-
operative day 1. Patients in cohort A and B were separ-
ately randomized using a web-based randomizer for
clinical trials [26]. In the previous Catastim 1 trial taking
place in the same ICU [24], the NMES and control
groups had slightly different Simplified Acute Physiology
Score II (SAPS II) scores. Hence, in the Catastim 2 trial,
randomization was stratified by the SAPS II score on the
first postoperative day to ensure balance of the NMES
and control groups with respect to disease severity. The
four strata were deduced from the quartiles of SAPS II
scores in a retrospective analysis of 2708 patients of the
same ICU.
Intervention
In the intervention group, all parts of the quadriceps
muscle (rectus femoris muscle, vastus intermedius
muscle, vastus lateralis muscle, vastus medialis muscle)
of both thighs were electrically stimulated. The muscles
were stimulated twice a day (2 × 30 minutes of NMES
with an interval of at least 30 minutes between both ses-
sions [24]) 7 days a week during the entire ICU stay but no
longer than 14 days, starting on postoperative day 1. High-
est tolerable intensity just below the pain threshold was ap-
plied. A visible and palpable contraction was the goal to
achieve. The Compex 3 Professional (CefarCompex Med-
ical AB, Freiburg, Germany) stimulator delivered biphasic
rectangular pulses of 0.4 ms pulse duration at 66 Hz [19].
The duty cycle was 3.5 s on and 4.5 s off, ramping up and
down were both set at 0.5 s [24]. Dual Snap (5 × 10 cm and
5 × 5 cm) electrodes (CefarCompex Medical AB) were used.
In the control group, the electrodes were applied, con-
nected to the stimulator, but no electricity was delivered.
Patients were blinded to the intervention: All patients were
told they would get NMES, whether or not electricity was
delivered.
Outcomes
Muscle layer thickness (MLT)
For all patients, MLT of the quadriceps muscle of both
thighs using two-dimensional B-mode ultrasound (Vivid i,
General Electric Healthcare, Little Chalfont, UK) was
measured on postoperative day 1, every other day until
ICU discharge and at hospital discharge. Patients in co-
hort A had an additional assessment of MLT before sur-
gery. In cohort A, the preoperative assessment took place
on the preoperative day in most patients (n = 23). Due to
postponement of surgery, the preoperative assessment
was between 2 and 8 days before surgery in six patients.
In previous studies [7, 27, 28] the cross-sectional area of
the rectus femoris muscle was measured. However, the
rectus femoris muscle only constitutes approximately
10 % of the total quadriceps cross-sectional area [29].
Even though there is no data about differing wasting rates
of the quadriceps muscle components in critically ill pa-
tients, hypertrophy may occur at different rates in the
quadriceps muscle components in healthy young males
during training [30]. Thus we measured not a cross-
sectional area of a single muscle, but the muscle layer
thickness of all parts of the quadriceps muscle. During the
ICU stay, edema may enlarge the cross-sectional area of
the muscle. Furthermore the ultrasound transducer is only
3.8 cm wide. Thus it is impossible to measure all parts of
the quadriceps muscle at only one measuring point by
ultrasonography. In order to account for all parts of the
quadriceps muscle in the most reliable way, we used three
measuring points per leg in two orthogonal planes to in-
crease precision. Twelve measurements per patient per
observation day were averaged to account for all parts of
the quadriceps muscle. Three measuring points per leg
were marked with a permanent marker pen for scanning
in the transverse and sagittal plane to make sure that the
exact same measuring point was measured across time
[31]: (1) lateral point: in the middle of the distance be-
tween the superior border of the greater trochanter and
the lateral knee joint space; (2) ventral point: on a line
from the anterior superior iliac spine to the superior
border of the patellar base, on the same level as the lateral
point; (3) medial point: on a line from the pubis to the
medial knee joint space, on the same level as the lateral
point. Frequency was set at 6 MHz. A pillow was placed
under the patient’s knees to ensure muscular relaxation. A
gel pad (Geliperm 260 × 120 × 3.3 mm, Geistlich Pharma,
Wolhusen, Switzerland) placed on the patient’s thigh and
additional ultrasound gel was used to apply the least
amount of pressure necessary while scanning until the
muscles were neatly displayed. Prior to trial start, inter-
examiner variation in MLT scanning between the five
trained assessors was assessed on 24 measuring points.
The intra-class correlation coefficient (ICC) for the five
assessors was 0.9 (95 % CI, 0.82 to 0.95) (P < 0.001). The
five nonblinded assessors effectuated the ultrasound scans
and muscle strength assessment and then applied the elec-
trodes for NMES or sham stimulation. During the recruit-
ment phase, none of the nonblinded assessors had access
to any actual MLT values. Thus it appears unlikely that
any observer bias was introduced by the nonblinded asses-
sors who effectuated the ultrasound scans. After the end
of data collection, MLT was evaluated with the software
EchoPAC (General Electric Healthcare). The two evalua-
tors were blinded to whether the patient belonged to the
Fischer et al. Critical Care  (2016) 20:30 Page 3 of 13
NMES or control group. Scans were evaluated per patient
from the first to the last taken ultrasound scan to ensure
consistency since muscular form is very individual. In that
way, the level of the fascia lata could be discerned consist-
ently in each patient. In a pilot testing we observed that
the intramuscular fascia cannot be precisely delimitated
from the muscular parts in patients during early ICU stay
(Fig. 1 and Additional file 1). Thus we opted to measure
the entire muscle layer thickness from the fascia lata (or
deep fascia) to the femur, because these two landmarks
can be precisely delineated. Beginning in the exact center
of the scan at the level of the lowest layer of the fascia lata,
MLT was measured down to the femur drawing the
shortest possible line. At the lateral measuring point in
the transverse and sagittal plane, MLT of vastus lateralis
and vastus intermedius muscles was measured from the
lowest layer of the fascia lata to the femur (Fig. 1 and
Additional file 1). Similarly, MLT of rectus femoris and
vastus intermedius muscles was measured in both
planes at the ventral measuring point and MLT of vas-
tus medialis and vastus intermedius muscles at the med-
ial measuring point. MLT measurement in both the
sagittal and transverse plane of one measuring point is
shown in Additional file 1. MLT measured in the trans-
verse plane highly correlated with the corresponding
MLT measured in the sagittal plane (r = 0.97, P < 0.001).
We averaged the tranverse and sagittal measurements
for each measuring point. This accounts for interscan
variation per measuring point. Since preliminary results
indicated that the mean of all six measuring points in
both planes is representative of all 12 measurements,
mean MLT of all 12 measurements was calculated for
each observation day.
Muscle strength
For all patients, muscle strength was measured on post-
operative day 1 or as soon as they were awake, every day
until ICU discharge and at hospital discharge. The pa-
tient was considered awake when he could follow orders,
which is necessary for evaluation of active muscle contrac-
tions. Patients in cohort A had an additional assessment
of muscle strength before surgery. Based on the diagnostic
criteria of ICUAW, which is established when mean MRC
score of all testable muscle groups is below 4 [5], muscle
strength was evaluated in all muscle groups of the upper
and lower extremities using the MRC scale [32]. Mean
MRC score of all muscle groups was calculated [5]. In
addition quadriceps mean MRC score was calculated as
mean MRC score of knee extension and hip flexion of
both legs to evaluate the function of the electrically stimu-
lated quadriceps muscles. According to the MRC scale
[33], mean MRC score ranges from a minimum of 0 to a
maximum of 5 points. Bilateral grip strength was mea-
sured with a Jamar hand dynamometer (Jamar, Duluth,
MN, USA). Patients were asked to perform the hand
dynamometer test twice for each side and the highest
value was noted for each side.
Functional outcomes
For all patients, the Functional Independence Measure
(FIM) score [34], the Timed Up and Go test [35] and the
12-Item Short Form (SF-12) health survey [36] were eval-
uated at hospital discharge. The average mobility level
proposed by Brown [37] was assessed at ICU and hospital
discharges. Patients in cohort A had an additional assess-
ment of all functional outcomes before surgery.
Fig. 1 Ultrasound scans of the left thigh at the lateral measuring point in the sagittal plane (Patient no. 104, control group)
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Patient satisfaction
At ICU discharge, patients were asked if the NMES/
sham stimulation was comfortable or uncomfortable.
Statistical analysis
In the previous Catastim 1 trial [24], MRC muscle
strength was evaluated for hip flexion: mean changes in
MRC score from the first postoperative day until ICU
discharge were −0.80 points [standard deviation (SD),
0.70 points] in the NMES group (n = 20) versus −1.75
points (SD, 1.52 points) in the control group out of a
maximum MRC score of 5 points (n = 20) (P = 0.015).
Based on these results, sample size calculation with Stata
yielded 25 patients per group at a two-sided significance
level of α = 0.05 and 80 % power. Assuming a dropout
rate of 20 %, 60 patients needed to be randomized.
All data was analyzed according to the intention-to-
treat principle with no imputation for any missing data.
Normality was assessed with Kolmogorov-Smirnov and
Shapiro-Wilk statistics. If quantitative variables were
normally distributed, they were expressed as mean ± SD
or 95 % confidence interval (CI). If they were not nor-
mally distributed, median (range) was indicated.
In previous muscle ultrasound studies, linear regres-
sion analyses were performed [7, 27, 28]. Similarly, we
presented results of actual raw data (Additional file 2
and Table 7) and results based on linear regression mod-
eling (Tables 2, 3, 4, 5, 6 and Additional file 3). Linear
mixed models were used to assess the treatment effects
while accounting for the repeated measurements per pa-
tient. Thus, the random effect ‘patient’ was defined in
each model. Linear mixed models were calculated for
mean MLT, mean MRC score of all muscle groups,
quadriceps mean MRC score and grip strength. Fixed ef-
fects of interest were postoperative day or study day,
NMES/control group, interaction between NMES/con-
trol group and postoperative day, and daily fluid balance
in the ICU. Fixed effects were either considered as quan-
titative or categorical variables: for example, the postop-
erative day or the daily fluid balance at the ICU were
quantitative variables. The study day (preoperative day,
first postoperative day, ICU discharge, hospital dis-
charge) or the group (NMES group, control group) were
categorical variables. By definition the results presented
as linear mixed models are derived statistics by linear re-
gression modeling (‘proc mixed’ in SAS software version
9.4; SAS Institute Inc., Cary, NC, USA).
Because of bandages to protect arterial catheters, pa-
tients were not always able to perform every movement
in all 12 muscle groups. If there were missing values for
muscle groups, mean MRC score was calculated for the
muscle groups that could be assessed. Similarly, due to
armboards because of radial arterial catheter, patients
were not always able to perform the hand dynamometer
test on both sides. Thus, either the right or left grip
strength was chosen for statistical analysis per patient
according to the lowest number of missing values over
all study days on each side. If the number of missing
values was equal for right and left grip strength for a pa-
tient, either the right or left grip strength was chosen ac-
cording to the highest mean grip strength over all study
days on each side.
In addition, intraoperative fluid balance, changes over
time in MLT or mean MRC score were compared be-
tween both groups with independent-groups t tests or
Mann-Whitney U tests as appropriate. Change in MLT
was correlated with the cumulative fluid balance in the
first three postoperative days with Pearson product-
moment correlation.
The secondary functional outcomes were evaluated in a
sensitivity analysis for patients seen both on preoperative
day and at hospital discharge (n = 12) in order to evaluate
whether preoperative functional levels could be regained
at hospital discharge. Changes over time in secondary
functional outcomes were analyzed with Wilcoxon
signed-rank tests. Changes in functional outcomes were
compared between both groups with Mann-Whitney U
tests. The patient satisfaction related to the intervention
was evaluated in 42 patients with Pearson’s chi-squared
test or Fisher’s exact test as appropriate.
Significance level was set at 0.05. All P values were two-
tailed. For statistical analysis, SPSS version 22 (IBM Corp.,
Armonk, NY, USA) and SAS version 9.4 were used. For fig-
ure construction, GraphPad Prism version 6.0 (GraphPad
Software, Inc., La Jolla, CA, USA) was used.
Results
Patients
Fifty-four patients were included in the intention-to-
treat analysis: 27 belonged to the NMES group and 27
to the control group (Fig. 2). All baseline characteristics
were comparable in both groups except for dobutamine
and noradrenaline doses in the ICU (Table 1).
NMES
Median duration of the electrical or sham stimulation
was 4 days (range, 2–13 days) in the NMES group and 4
days (range, 1–14 days) in the control group. In the
NMES group, median NMES intensities were 40.5 mA
(range, 2–100 mA) for the right thigh and 40 mA (range,
5–120 mA) for the left thigh. In terms of adherence,
only 9 out of 145 NMES sessions and 6 out of 154 sham
stimulation sessions could not have been carried out.
Muscle layer thickness (MLT)
MLT was evaluated in 53 out of 54 patients. Due to
technical reasons, ultrasound scans of one patient could
not be saved. MLT was not evaluated in 210 of all 2825
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ultrasound scans, because the muscles of the thigh
could not be clearly delimited (Additional file 4). MLT
increased from preoperative day to the first postopera-
tive day by 0.41 cm (95 % CI of estimate, 0.24 to 0.59 cm)
(P < 0.001) (Table 3). Intraoperative fluid balance was
4856.5 ± 2637.4 ml (mean ± SD) in the NMES group
(n = 26) and 4111.9 ± 1766.6 ml (mean ± SD) in the
control group (n = 26) (P = 0.24). During the first three
postoperative days, there was a positive correlation be-
tween change in MLT and cumulative fluid balance
(r = 0.43, P = 0.01) (n = 41). From the first postopera-
tive day, MLT decreased by 0.08 cm (95 % CI of es-
timate, −0.11 to −0.06 cm) per day (P < 0.001). The
change in MLT of −0.08 cm per day is the result of the lin-
ear regression from the first postoperative day where each
patient is considered as a random factor. Overall this
means that MLT decreases by 8 mm (95 % CI, −11 to −6
mm) in 10 days by linear regression modeling (Table 2).
This corresponds to a 25 % decrease in muscle layer
thickness in 10 days. The NMES intervention had no
significant effect on MLT (Table 2). At ICU discharge,
MLT was about 0.18 cm (95 % CI of estimate, −0.004 to
0.37 cm) higher than on preoperative day (P = 0.055)
(Table 3). At hospital discharge, MLT was about 0.28
cm (95 % CI of estimate, −0.49 to −0.06 cm) lower than
on preoperative day (P = 0.01) (Table 3). Time variation
of actual MLT values in individual patients is shown in
Additional file 2.
Muscle strength
Out of all 54 patients, 36 patients were awake on post-
operative day 1, 7 patients on postoperative day 2 or 3, 8
patients on postoperative days 4 to 7 in order to perform
the first postoperative MRC measurement in the ICU.






54 ICU stay < 48 h
3 Lost due to transfer to another ICU ward
2 Withdrew consent
2 Did not undergo surgery
1 Open wounds in stimulation area
1 Too unstable postoperative medical state
17 Randomized to 
NMES
2 Withdrew consent




stay < 48 h




stay < 48 h
15 Randomized to 
sham-stimulation
1 Too unstable 
medical state
1 Unexpected ICU 
stay < 48 h
34 Randomized 29 Randomized
3 Lost to follow-up at ICU
discharge                                        
1 Discontinuation of  
NMES
1 Death in the ICU
5 Lost to follow-up at 
hospital discharge 
6 Lost to follow-up at ICU
discharge 
1 Discontinuation of   
sham-stimulation
3 Death in the ICU
6 Lost to follow-up at 
hospital discharge
3 Lost to follow-up at ICU
discharge 
2 Transfer from ICU to  
other hospital 
3 Lost to follow-up at 
hospital discharge
1 Lost to follow-up at ICU
discharge 
1 Transfer from ICU to  
other hospital
6 Lost to follow-up at 
hospital discharge
15 Included in the 
intention-to-treat analysis
14 Included in the 
intention-to-treat analysis
12 Included in the 
intention-to-treat analysis
13 Included in the 
intention-to-treat analysis
Fig. 2 Flow diagram of the Catastim 2 trial
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Three patients remained sedated during the first 14
postoperative days and were not able to undergo MRC
evaluation during their ICU stay. All patients in cohort A,
who were assessed before surgery, had normal muscle
strength (mean MRC score of 4.92 points (3.83 to 5 points),
median (range), in the NMES group versus 4.92 points
(3.67 to 5 points), median (range), in the control group) (P
= 0.96). Mean MRC score of all muscle groups decreased
from preoperative day to the first postoperative day by 0.57
points (95 % CI of estimate, −0.78 to −0.36 points) (P <
0.001) (Table 5). The decrease in mean MRC score of all
muscle groups from preoperative day to postoperative day
1 was significantly higher in the NMES group [median
(range): −0.65 points (−1.82 to 0 points)] than in the





Age, mean (SD), y 63.3 (15.5) 69.7 (13.1)
Male sex, no. (%) 18 20
Body mass index, mean (SD) 27.6 (3.7) 27.7 (4.6)
SAPS II at postoperative day 1,
median (range)
26.0 (7–46) 24.0 (7–47)
SOFA at postoperative day 1,
median (range)
9.0 (1–15) 7.0 (1–11)
Period ventilated, median
(range), da
2 (1–7) 2 (1–15)
ICU length of stay, median
(range), db
6 (3–23)c 7 (3–213)c
ICU readmission, no. (%) 4 (14.8) 3 (11.1)
ICU readmission, median
(range), db
2 (1–35) 6 (1–41)
Hospital length of stay,
median (range), db
22 (4–84)d 19 (9–213)d
Mortality, no (%)
in the ICU 1 (3.7) 3 (11.1)
at the surgical ward 0 0
Single surgical procedure, no. (%)e 17 (63.0) 17 (63.0)
Double surgical procedure, no. (%)e 7 (25.9) 7 (25.9)
Triple surgical procedure, no. (%)e 3 (11.1) 3 (11.1)
Surgery type, no. of procedures (%
in relation to total no. of procedures)
Aortic valve replacement 9 (22.5) 11 (27.5)
Coronary artery bypass grafting 11 (27.5) 8 (20)
Heart transplantation 6 (15) 5 (12.5)
Other cardiothoracic
surgery typef
4 (10) 4 (10)
Mitral valve replacement 2 (5) 5 (12.5)
Mitral valve reconstruction 4 (10) 3 (7.5)
Tricuspid valve reconstruction 3 (7.5) 2 (5)
Bentall procedure 1 (2.5) 2 (5)
Comorbidities present in 96.3 % of the
study population, no. (%)
Coronary heart disease 12 (44.4) 8 (29.6)
Hypertension 9 (33.3) 7 (25.9)
Myocardial infarction 7 (25.9) 4 (14.8)
Atrial fibrillation 2 (7.4) 8 (29.6)
Diabetes 5 (18.5) 4 (14.8)
Obesity 3 (11.1) 6 (22.2)
Chronic obstructive
pulmonary disease
6 (22.2) 3 (11.1)
Hyperlipidemia 4 (14.8) 4 (14.8)
Malignoma 2 (7.4) 5 (18.5)
Carotid artery stenosis 2 (7.4) 2 (7.4)
Table 1 Baseline characteristics of patients (Continued)
Patients receiving medication in the ICU, no. (%)
Opioids 26 (96.3) 26 (96.3)
Insulin 25 (92.6) 26 (96.3)
Dobutamine 21 (77.8) 17 (63)
Noradrenaline 18 (66.7) 18 (66.7)
Glucocorticoids 11 (40.7) 6 (22.2)
Benzodiazepines 6 (22.2) 6 (22.2)
Neuromuscular blockers 4 (14.8) 2 (7.4)
Intake days, median (range), d
Opioids 3 (1–10) 3 (1–14)
Insulin 4 (1–9) 4 (1–14)
Dobutamine 4 (2–12) 5 (1–14)
Noradrenaline 2 (1–9) 4.5 (1–14)
Glucocorticoids 3 (1–7) 3.5 (1–14)
Benzodiazepines 1 (1–4) 1 (1–9)
Neuromuscular blockers 1 (1–1) 1 (1–1)
Dose, median (range), μg/kg/min
Dobutamine 2.78 (0.52–7.59)g 4.12 (0.82–10.53)g
Noradrenaline 0.07 (0.01–0.54)h 0.12 (0.002–0.88)h
NMES neuromuscular electrical stimulation, SD standard deviation, SAPS II
Simplified Acute Physiology Score II, SOFA Sequential Organ Failure
Assessment, ICU intensive care unit
aThe ventilation period was calculated as the number of calendar days from
the day of surgery (counted as 1 day) to the last day of ventilation (also
counted as 1 day). All patients were ventilated when transferred from the
operating room to the ICU
bThe time period was calculated as the number of calendar days from the day
of ICU/hospital (re)admission (counted as 1 day) to the day of ICU/hospital




eExample of single surgical procedure: aortic valve replacement; example of
double surgical procedure: aortic valve replacement + coronary artery bypass
grafting; example of triple surgical procedure: aortic valve replacement +mitral
valve reconstruction + coronary artery bypass grafting
fAtrial septal defect II closure, pericardial tamponade, lung transplantation,
resection of cardiac aneurysm, aortic arch replacement, Glenn procedure, Ross
procedure, replacement of ascending aorta
gP < 0.001
hP = 0.01
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control group [median (range): −0.11 points (−2.36 to 0.18
points)] (P = 0.046). Thus, even before the NMES interven-
tion began, patients randomized to the NMES group had a
weaker mean MRC of −0.45 points (95 % CI of estimate,
−0.88 to −0.03 points, P = 0.04) than patients randomized
to the control group at the starting point, which was the
first postoperative day (Table 4). This is unrelated to the
NMES intervention because the intervention started only
afterwards. After the onset of the NMES intervention, pa-
tients in the NMES group had a 4.5 times higher slope in
recovering muscle strength than patients in the control
group by linear regression modeling [0.09 MRC points per
day (95 % CI of estimate, 0.03 to 0.14 MRC points per day)
in the NMES group versus 0.02 MRC points per day (95 %
CI of estimate, −0.02 to 0.05 MRC points per day) in the
control group] (Table 4). Finally, mean MRC score of all
muscle groups regained preoperative values at hospital dis-
charge independent of group allocation (P = 0.43) (Table 5).
Time variation of actual mean MRC score of all muscle
groups in individual patients is shown in Additional file 2.
Analysis of quadriceps mean MRC showed similar results
to those of mean MRC of all muscle groups (Additional
file 3). Patients had lost 4 kilogram-force (95 % CI of
estimate, −6.90 to −1.09 kilogram-force) in hand grip
Table 2 Linear mixed model for MLT from the first
postoperative day for a maximum of 14 postoperative days
(53 patients, 183 observations)
Estimate of MLT in
cm (95 % CI)
P value
Intercept 3.87 (3.58 to 4.15) <0.001
Postoperative day −0.08 (−0.11 to −0.06) <0.001
Control group Reference .
NMES group −0.18 (−0.59 to 0.23) 0.38
Postoperative day × Control group Reference .
Postoperative day × NMES group 0.02 (−0.01 to 0.06) 0.21
Daily fluid balance in the ICU −0.04 (−0.08 to 0.01) 0.09
MLT muscle layer thickness, CI confidence interval, NMES neuromuscular
electrical stimulation, ICU intensive care unit
Table 3 Linear mixed model for MLT on four important study
days (53 patients, 141 observations)
Estimate of MLT in cm (95 % CI) P value
Intercept 3.26 (2.99 to 3.52) <0.001
Preoperative day Reference .
First postoperative day 0.41 (0.24 to 0.59) <0.001
ICU discharge 0.18 (−0.004 to 0.37) 0.055
Hospital discharge −0.28 (−0.49 to −0.06) 0.01
Control group Reference .
NMES group −0.16 (−0.49 to 0.16) 0.32
MLT muscle layer thickness, CI confidence interval, ICU intensive care unit,
NMES neuromuscular electrical stimulation
Table 4 Linear mixed model for mean MRC of all muscle
groupsa from the first postoperative day for a maximum of 14
postoperative days (51 patients, 220 observations)
Estimate of mean MRC
in pointsa (95 % CI)
P value
Intercept 4.10 (3.80 to 4.39) <0.001
Postoperative day 0.02 (−0.02 to 0.05) 0.40
Control group Reference .
NMES group −0.45 (−0.88 to −0.03) 0.04
Postoperative day × Control group Reference .
Postoperative day × NMES group 0.09 (0.03 to 0.14) 0.002
Days of ICU and hospital discharge, where no NMES was applied anymore,
were excluded in this model
The linear mixed model for mean MRC in Table 4 reads as follows:
MRC = 4.10 + (0.02 × postoperative day) - (0.45 × NMES group) + (0.09 ×
postoperative day × NMES group)
0.02 is the slope of MRC time variation in the control group, which is the
reference group: for each postoperative day, MRC increases by 0.02 points
(95 % CI, −0.02 to 0.05 points) in the control group (P = 0.40)
0.45 represents the lower starting point in the NMES group on the first
postoperative day before the NMES intervention began: on the first
postoperative day, MRC was about −0.45 points (95 % CI, −0.88 to −0.03
points) lower in the NMES group than in the control group (P = 0.04)
0.09 is the slope of MRC time variation in the NMES group: the slope of MRC
time variation is 4.5 times higher than the slope in the control
group (P = 0.002)
MRC Medical Research Council, CI confidence interval, NMES neuromuscular
electrical stimulation
aAccording to the MRC scale [33], mean MRC score ranges from a minimum of
0 to a maximum of 5 points
Table 5 Linear mixed model for mean MRC of all muscle
groups on four important study days (51 patients, 130
observations)
Estimate of mean MRC
in pointsa (95 % CI)
P value
Intercept 4.69 (4.45 to 4.93) <0.001
Preoperative day Reference .
First postoperative day −0.57 (−0.78 to −0.36) <0.001
ICU discharge −0.27 (−0.48 to −0.06) 0.01
Hospital discharge 0.10 (−0.15 to 0.35) 0.43
Control group Reference .
NMES group 0.01 (−0.26 to 0.28) 0.92
The linear mixed model for mean MRC in Table 5 reads as follows:
On the first postoperative day mean MRC was about −0.57 points (95 % CI,
−0.78 to −0.36 points) lower than on preoperative day, which is the reference
day (P < 0.001)
At ICU discharge mean MRC was about −0.27 points (95 % CI, (−0.48 to −0.06
points) lower than on preoperative day (P = 0.01)
At hospital discharge mean MRC was not different from mean MRC on
preoperative day (P = 0.43)
On preoperative day, at the first postoperative day, at ICU discharge and at
hospital discharge there were no differences in mean MRC between the NMES
and control group (P = 0.92)
MRC Medical Research Council, CI confidence interval, ICU intensive care unit,
NMES neuromuscular electrical stimulation
aAccording to the MRC scale [33], mean MRC score ranges from a minimum of
0 to a maximum of 5 points
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strength at hospital discharge compared to preoperative
day (P = 0.008) (Table 6). The NMES intervention had no
significant effect on grip strength (Table 6).
Functional outcomes
The secondary functional outcomes were evaluated for
patients seen both on preoperative day and at hospital
discharge (n = 12). The average mobility level and FIM
score significantly decreased from preoperative day to
hospital discharge (Table 7). On the other hand, the
Timed Up and Go Test as well as the mental component
score (MCS-12) and physical component score (PCS-12)
of the SF-12 regained preoperative levels at hospital dis-
charge (Table 7). Changes in all functional outcomes
from preoperative day to ICU or hospital discharge were
not significantly different between both groups.
Patient satisfaction
Forty-two patients were asked about their satisfaction
with the NMES/sham stimulation. Out of 42 patients, 12
patients in the NMES group and 5 patients in the con-
trol group had a comfortable sensation (P = 0.03). Five
patients in the NMES group and no patient in the con-
trol group had a feeling of discomfort (P = 0.048).
Discussion
In this randomized controlled trial, NMES had no effect
on MLT, but was associated with a higher rate in regain-
ing muscle strength during the ICU stay. At hospital dis-
charge, all patients regained preoperative levels of
muscle strength evaluated with the MRC scale, but still
showed residual functional disability and decreased MLT
compared to pre-ICU levels.
Muscle layer thickness (MLT)
The increase in MLT from preoperative day to postoper-
ative day 1 can be attributed to the surgically induced
inflammation and to the positive intraoperative fluid
balance. Fluid is entering the muscle, since cumulative
fluid balance and change in MLT positively correlate in
the first three postoperative days. Postoperatively, MLT
progressively decreased until ICU discharge, but was still
higher at ICU discharge than on preoperative day. This
implies that the intramuscular edema regressed, but was
still present at ICU discharge. Only at hospital discharge,
MLT was lower than on preoperative day. This clearly
indicates that also MLT was lost. It is not possible to tell
at what time muscle loss started, since measurement of
MLT was highly affected by intramuscular edema.
In the Catastim 2 study, NMES had no effect on MLT.
Edema could have led to dissipation of the electrical
current so that the current reaching the intramuscular
motor nerve branches was not sufficient to generate
muscle contractions. Segers [38] demonstrated that pa-
tients with high edema had insufficient muscle contrac-
tions during NMES. Segers found that patients had
more sufficient NMES muscle contractions at the begin-
ning of their ICU stay than after 1 week of ICU stay.
However they did not analyze whether this was attrib-
uted to changes in development of edema or sepsis. In
our study the positive correlation between cumulative
fluid balance and change in MLT during the first three
postoperative days suggests that edema is predominant
in the early stage of surgical critical illness. Hence the ef-
fects of NMES may be rather reduced in the first days of
critical illness. In the first ICU week, up to 62 % of all
patients had a nonexcitable muscle membrane [39],
which may also attenuate the effects of NMES.
So far, only three studies [9, 19, 40] showed an effect
of NMES on muscle mass in critically ill patients. How-
ever variation in muscle mass was not compared to pre-
ICU values and fluid status was not considered as a con-
founder for measurement of muscle mass in these stud-
ies [9, 19, 40]. The Catastim 2 study indicates that the
postoperative decrease in MLT at the ICU is not only
due to loss of muscle mass, but also to reduction of
intramuscular edema.
Muscle strength
The decrease in MRC strength from preoperative day to
postoperative day 1 is most likely due to the surgical
event and the postoperative sedation. Even before the
NMES intervention began, the decrease in MRC from
preoperative day to postoperative day 1 was coinciden-
tally more pronounced in patients randomized to the
NMES intervention than in patients randomized to the
control group. After the onset of the NMES interven-
tion, patients in the NMES group had a 4.5 times higher
slope in recovering muscle strength during the ICU stay
than patients in the control group. This indicates that
the NMES intervention promotes a faster regain of
muscle strength during the ICU stay. Still, both groups
Table 6 Linear mixed model for grip strength measured by
hand dynamometer on four important study days (49 patients,
127 observations)
Estimate of mean MRC
in kilogram-force (kgf) (95 % CI)
P value
Intercept 30.18 (25.63 to 34.73) <0.001
Preoperative day Reference .
First postoperative day −11.55 (−13.98 to −9.11) <0.001
ICU discharge −8.00 (−10.47 to −5.52) <0.001
Hospital discharge −4.00 (−6.90 to −1.09) 0.008
Control group Reference .
NMES group 0.89 (−5.16 to 6.94) 0.77
MRC Medical Research Council, CI confidence interval, ICU intensive care unit,
NMES neuromuscular electrical stimulation
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were able to regain preoperative MRC values at hospital
discharge. Nevertheless, a faster recovery may be benefi-
cial and is an interesting result. Moreover, it shows that
it is important to consider the factor time in the analysis
of time variation of muscle strength in the ICU. No pre-
vious study [16–18, 21, 22] yet accounted for an inter-
action between NMES and observation day in a linear
regression model.
Similar to our results, Kho’s study [16] showed a higher
increase in MRC from ICU awakening to ICU and hos-
pital discharges in the NMES group. In Kho’s study, the
absolute MRC values at hospital discharge were not differ-
ent between both groups. Unfortunately, Kho did not as-
sess MRC prior to the ICU in order to determine whether
both groups could regain their preoperative muscle
strength levels. Other studies also showed positive effects
of NMES on the MRC score in ICU patients [16–18, 20–
22]. In line with these previous studies, the Catastim 2
study shows that NMES contributes to a faster recovery of
muscle strength during the ICU stay.
Functional outcomes
In contrast to the recovery of muscle strength, patients
did not regain their preoperative levels of mobility (aver-
age mobility level) and functional abilities (FIM score) at
hospital discharge, independent of group allocation. This
indicates that muscle strength and mobility may not be
similarly affected by ICUAW. Similar to our results, Kho
et al. [16] showed that the preoperative functional status
score for the intensive care (FSS-ICU) score, which is
similar to the FIM score, was not regained at hospital dis-
charge, independent of group assignment. These func-
tional disabilities at hospital discharge still persist 2
months to 5 years later as other trials have shown. After
hospital discharge patients may regain their muscle
strength, but not their functional abilities: patients with
lower muscle strength at hospital discharge regained
strength within 12 months [41]. However patients with
lower muscle strength at hospital discharge still had lower
SF-36 physical component score and lower 6-minute
walking distance (6MWD) 3, 6, 12 and 24 months after
ICU discharge [41]. Similarly, ICU survivors spent only
3 % of their time walking and 90 % of their time inactive
at 2 months after ICU discharge [42]. Their 6MWD was
also decreased [42]. Likewise, Wieske [43] showed that pa-
tients with lower muscle strength during their ICU stay
had lower SF-36 physical functioning 6 months after ICU
discharge. Needham [44] also showed that acute lung in-
jury survivors had lower 6MWD and SF-36 at 6 and 12
months after hospital discharge in comparison to normal
predicted values. Even at 5 years after ICU discharge,
6MWD and SF-36 were reduced [3]. These impressive re-
sults clearly show that ICUAW is a public health issue go-
ing beyond hospital discharge, which calls for prophylactic
or therapeutic measures. In our study, NMES had no ef-
fect on functional outcomes at hospital discharge. Yet, our
sensitivity analysis for the secondary functional outcomes
only included a small patient subcategory (n = 12) seen
both on preoperative day and at hospital discharge. The
sensitivity analysis was chosen in order to determine
whether preoperative functional levels could be regained
at hospital discharge. Positive effects of early mobilization
on functional outcomes were shown in other studies:
Schweickert [15] showed that sedation interruptions and
physical therapy led to better functional outcomes at hos-
pital discharge. Abdellaoui [18] found an increase in
6MWD in the NMES group. Zanotti [22] observed that
NMES reduced the number of days needed to transfer
from bed to chair. Parry [45] showed that combined elec-
trical stimulation and cycling in critically ill patients led to
a shorter delirium period.
Limitations
Even before the NMES intervention started, patients ran-
domized to the NMES group had a higher decrease in
MRC score than patients randomized to the control group.
This higher decrease in MRC at the first postoperative day
may also contribute to a higher rate in recovering MRC in
the NMES group during the ICU stay. Hence, the higher
rate in recovering MRC during the ICU stay may not be
due to the NMES intervention alone, but also partly to the
coincidentally higher decrease in MRC from preoperative
day to the first postoperative day in the NMES group.
Table 7 Functional outcomes on four important study days (12 patients)
Preoperative day ICU discharge Hospital discharge P for change from preoperative
day to hospital discharge
Average mobility level, median (range) 12 (12–12) 2 (0–11)a 12 (8–12)b 0.04
FIM score, median (range) 125.0 (119–126) 122.0 (82–126) 0.02
Timed Up and Go Test, median (range) 11.5 (7–20) 11.5 (1–28) 0.24
MCS-12, median (range) 52.82 (25.05–64.63) 51.91 (29.42–64.08) 0.88
PCS-12, median (range) 40.02 (17.91–61.61) 32.58 (27.46–45.90) 0.53
ICU intensive care unit, FIM Functional Independence Measure, MCS-12 mental component score of the SF-12, PCS-12 physical component score of the SF-12
aP for change from preoperative day to ICU discharge: 0.002
bP for change from ICU discharge to hospital discharge: 0.002
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The average mobility level was initially suggested by
Brown in 2004 in the Journal of the American Geriatrics
Society [37]. The average mobility level proposed by
Brown is not mentioned among measurement instru-
ments for impairments in the critically ill patient in Parry’s
systematic review [46]. There may be better functional
scores to assess mobility. On the other hand, the FIM
score is recommended in Parry’s systematic review [46].
Outlook
Visualizing or palpating the NMES contractions was
hardly possible in patients with high fluid retention in our
study and in Seger’s study [38]. Therefore it should be
verified by ultrasonography whether muscles are contract-
ing sufficiently during NMES in the presence of edema.
The assessment of baseline values prior to surgery or
acute illness is of paramount importance in order to ad-
just for confounders related to surgery such as inflamma-
tion, fluid balance and sedation. Fluid balance should be
taken into account when MLT is assessed by ultrasonog-
raphy. Due to the lack of combined assessment of pre-
operative muscle mass values and fluid balance in
previous studies, the formation and regression of intra-
muscular edema have never been shown before and need
to be thoroughly addressed in future.
In line with previous studies [41], it is not the loss in
muscle strength or mass but primarily the loss in func-
tional outcomes which may play the more significant
and patient-centered public health issue. Future studies
should especially study patient-centered functional out-
comes such as FIM, mobility and health-related quality
of life (HRQoL).
Conclusions
NMES had no effect on MLT, but was associated with a
higher rate in regaining muscle strength during the ICU
stay. Regression of intramuscular edema during the ICU
stay interfered with measurement of changes in MLT. At
hospital discharge, all patients had regained preoperative
levels of muscle strength evaluated with the MRC scale,
but still showed residual functional disability and de-
creased MLT compared to pre-ICU levels.
Key messages
 The NMES intervention had no effect on muscle layer
thickness, but was associated with a higher rate in
regaining muscle strength during the ICU stay.
 Patients regained preoperative levels of muscle
strength evaluated with the MRC scale by hospital
discharge, but still had residual functional disability.
This was independent of group allocation.
 The postoperative decrease in muscle layer thickness
is not only due to loss of muscle mass, but also to
reduction of intramuscular edema.
Additional files
Additional file 1: Ultrasound scan of the left thigh at the lateral
measuring point in the transverse and sagittal plane (Patient no.
104, control group) on postoperative day 3. (TIF 798 kb)
Additional file 2: Time variation of MLT and mean MRC of all
muscle groups in individual patients. Days of ICU and hospital
discharge are included. (PDF 837 kb)
Additional file 3: Linear mixed models for quadriceps mean MRCa
Table S1A. Linear mixed model for quadriceps mean MRC from the first
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was applied anymore, were excluded in this model. Table S1B. Linear
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group). MLT was not evaluated on postoperative day 1. (TIF 1045 kb)
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